Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C - PubMed (original) (raw)

. 2007 Mar 1;25(11):1969-92.

doi: 10.1016/j.vaccine.2006.11.051. Epub 2006 Dec 6.

Jose Luis Nájera, Victoria Jiménez, Kurt Bieler, Jens Wild, Linda Kostic, Shirin Heidari, Margaret Chen, Marie-Joelle Frachette, Giuseppe Pantaleo, Hans Wolf, Peter Liljeström, Ralf Wagner, Mariano Esteban

Affiliations

• PMID: 17224219
• DOI: 10.1016/j.vaccine.2006.11.051

Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C

Carmen Elena Gómez et al. Vaccine. 2007.

Abstract

Recombinants based on the attenuated vaccinia virus strains MVA and NYVAC are considered candidate vectors against different human diseases. In this study we have generated and characterized in BALB/c and in transgenic HHD mice the immunogenicity of two attenuated poxvirus vectors expressing in a single locus (TK) the codon optimized HIV-1 genes encoding gp120 and Gag-Pol-Nef (GPN) polyprotein of clade C (referred as MVA-C and NYVAC-C). In HHD mice primed with either MVA-C or NYVAC-C, or primed with DNA-C and boosted with the poxvirus vectors, the splenic T cell responses against clade C peptides spanning gp120/GPN was broad and mainly directed against Gag-1, Env-1 and Env-2 peptide pools. In BALB/c mice immunized with the homologous or the heterologous combination of poxvirus vectors or with Semliki forest virus (SFV) vectors expressing gp120/GPN, the immune response was also broad but the most immunogenic peptides were Env-1, GPN-1 and GPN-2. Differences in the magnitude of the cellular immune responses were observed between the poxvirus vectors depending on the protocol used. The specific cellular immune response triggered by the poxvirus vectors was Th1 type. The cellular response against the vectors was higher for NYVAC than for MVA in both HHD and BALB/c mice, but differences in viral antigen recognition between the vectors was observed in sera from the poxvirus-immunized animals. These results demonstrate the immunogenic potential of MVA-C and NYVAC-C as novel vaccine candidates against clade C of HIV-1.

PubMed Disclaimer

Similar articles

• Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
  Gómez CE, Nájera JL, Jiménez EP, Jiménez V, Wagner R, Graf M, Frachette MJ, Liljeström P, Pantaleo G, Esteban M. Gómez CE, et al. Vaccine. 2007 Apr 12;25(15):2863-85. doi: 10.1016/j.vaccine.2006.09.090. Epub 2006 Oct 16. Vaccine. 2007. PMID: 17113200
• HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
  García-Arriaza J, Perdiguero B, Heeney JL, Seaman MS, Montefiori DC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Self SG, Borate B, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Lee C, Kibler KV, Jacobs BL, Wagner R, Ding S, Pantaleo G, Esteban M. García-Arriaza J, et al. J Virol. 2017 Apr 13;91(9):e02182-16. doi: 10.1128/JVI.02182-16. Print 2017 May 1. J Virol. 2017. PMID: 28179536 Free PMC article.
• Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.
  Clarke DK, Cooper D, Egan MA, Hendry RM, Parks CL, Udem SA. Clarke DK, et al. Springer Semin Immunopathol. 2006 Nov;28(3):239-53. doi: 10.1007/s00281-006-0042-3. Epub 2006 Sep 15. Springer Semin Immunopathol. 2006. PMID: 16977404 Free PMC article. Review.
• Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.
  Esteban M. Esteban M. Hum Vaccin. 2009 Dec;5(12):867-71. doi: 10.4161/hv.9693. Epub 2009 Dec 3. Hum Vaccin. 2009. PMID: 19786840 Review.

Cited by

• Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium.
  Marcos-Villar L, Perdiguero B, Anthiya S, Borrajo ML, Lou G, Franceschini L, Esteban I, Sánchez-Cordón PJ, Zamora C, Sorzano CÓS, Jordá L, Codó L, Gelpí JL, Sisteré-Oró M, Meyerhans A, Thielemans K, Martínez-Jiménez F, López-Bigas N, García F, Alonso MJ, Plana M, Esteban M, Gómez CE. Marcos-Villar L, et al. NPJ Vaccines. 2024 Mar 6;9(1):53. doi: 10.1038/s41541-024-00838-8. NPJ Vaccines. 2024. PMID: 38448450 Free PMC article.
• Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein.
  Perdiguero B, Hauser A, Gómez CE, Peterhoff D, Sideris E, Sorzano CÓS, Wilmschen S, Schaber M, Stengel L, Asbach B, Ding S, Von Laer D, Levy Y, Pantaleo G, Kimpel J, Esteban M, Wagner R. Perdiguero B, et al. Front Immunol. 2023 Nov 17;14:1270908. doi: 10.3389/fimmu.2023.1270908. eCollection 2023. Front Immunol. 2023. PMID: 38045703 Free PMC article.
• Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate.
  Perdiguero B, Marcos-Villar L, López-Bravo M, Sánchez-Cordón PJ, Zamora C, Valverde JR, Sorzano CÓS, Sin L, Álvarez E, Ramos M, Del Val M, Esteban M, Gómez CE. Perdiguero B, et al. Front Immunol. 2023 Jun 19;14:1160065. doi: 10.3389/fimmu.2023.1160065. eCollection 2023. Front Immunol. 2023. PMID: 37404819 Free PMC article.
• Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?
  Horvath A, Rogers L, Pollakis G, Baranov O, Pieroth N, Joseph S, Chachage M, Heitzer A, Maganga L, Msafiri F, Joachim A, Viegas E, Eller LA, Kibuuka H, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Dhitavat J, Premsri N, Fidler S, Shattock RJ, Robb ML, Weber J, McCormack S, Munseri PJ, Lyamuya E, Nilsson C, Kroidl A, Hoelscher M, Wagner R, Geldmacher C, Held K. Horvath A, et al. Front Immunol. 2023 Jan 9;13:1075606. doi: 10.3389/fimmu.2022.1075606. eCollection 2022. Front Immunol. 2023. PMID: 36741409 Free PMC article.
• Single Immunization of a Vaccine Vectored by a Novel Recombinant Vaccinia Virus Affords Effective Protection Against Respiratory Syncytial Virus Infection in Cotton Rats.
  Russell MS, Thulasi Raman SN, Gravel C, Zhang W, Pfeifle A, Chen W, Van Domselaar G, Safronetz D, Johnston M, Sauve S, Wang L, Rosu-Myles M, Cao J, Li X. Russell MS, et al. Front Immunol. 2021 Sep 17;12:747866. doi: 10.3389/fimmu.2021.747866. eCollection 2021. Front Immunol. 2021. PMID: 34603336 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations

• Miscellaneous

  • NCI CPTAC Assay Portal